Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib plus docetaxel versus placebo plus docetaxel in previously treated KRAS-mutant advanced non-small cell lung cancer
NL-OMON40580Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of selumetinib and docetaxel, sponsored by AstraZeneca. Started Oct 2013; status: recruiting.
02
Drugs
selumetinibdocetaxel
Beyond the preview
Go deeper on NL-OMON40580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40580.